Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Benzolamide (CL 11366) inhibits carbonic anhydrase effectively and low-threshold calcium currents in hippocampal pyramidal neurons.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
5 mg | 在庫あり | ¥ 11,000 | |||
10 mg | 在庫あり | ¥ 18,500 | |||
25 mg | 在庫あり | ¥ 37,500 | |||
50 mg | 在庫あり | ¥ 57,000 | |||
100 mg | 在庫あり | ¥ 84,500 | |||
200 mg | 在庫あり | ¥ 125,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 12,000 |
説明 | Benzolamide (CL 11366) inhibits carbonic anhydrase effectively and low-threshold calcium currents in hippocampal pyramidal neurons. |
ターゲット&IC50 | CA (human):15 nM (Ki), VchCAγ:78 nM (Ki), CA II (human):9 nM (Ki), CAS3:54 nM (Ki), EcoCAγ:94 nM (Ki) |
In vitro | Benzolamide inhibits hCA I, hCA II, EcoCAγ and VchCAγ, with Kis of 15 nM, 9 nM, 94 nM and 78 nM, respectively[1]. Benzolamide shows selectivity for CAS3 with a Ki of 54 nM over CAS1 with a Ki of 2115 nM and CAS2 with a Ki of 410 nM[2]. |
In vivo | Administration of 90 μmol/kg Benzolamide decreases brain pH and suppresses electrographic post-asphyxia seizures in rats[3]. |
別名 | CL-11366, W 1803, CL 11366, CL11366, W-1803 |
分子量 | 320.37 |
分子式 | C8H8N4O4S3 |
CAS No. | 3368-13-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (780.35 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Benzolamide 3368-13-6 Metabolism Carbonic Anhydrase Inhibitor Carbonate dehydratase seizures CL-11366 CAS3 glaucoma W 1803 CL 11366 W1803 CL11366 inhibit W-1803 inhibitor